Artal Group’s Repare Therapeutics RPTX Stock Holding History

Artal Group’s Portfolio RPTX Stock Details RPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-700,000	Closed	-$3.3M	–	127
2024 Q1	$3.3M	Hold	700,000	–	–	0.08%	74
2023 Q4	$5.11M	Hold	700,000	–	–	0.17%	50
2023 Q3	$8.46M	Hold	700,000	–	–	0.36%	46
2023 Q2	$7.41M	Hold	700,000	–	–	0.23%	58
2023 Q1	$6.89M	Hold	700,000	–	–	0.41%	52
2022 Q4	$10.3M	Hold	700,000	–	–	0.57%	42
2022 Q3	$8.49M	Hold	700,000	–	–	0.36%	47
2022 Q2	$9.79M	Hold	700,000	–	–	0.52%	37
2022 Q1	$9.97M	Hold	700,000	–	–	0.42%	47
2021 Q4	$14.8M	Buy	700,000 +150,000	+27%	+$3.53M	0.4%	54
2021 Q3	$14.4M	Hold	550,000	–	–	0.32%	65
2021 Q2	$17.1M	Hold	550,000	–	–	0.35%	61
2021 Q1	$16.9M	Sell	550,000 -20,000	-4%	-$679K	0.3%	73
2020 Q4	$19.6M	Hold	570,000	–	–	0.42%	59
2020 Q3	$17.5M	Sell	570,000 -30,000	-5%	-$794K	0.43%	51
2020 Q2	$18.6M	Buy	+600,000	New	+$19.3M	0.52%	47

Other funds holding RPTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Artal Group's RPTX Position: Q2 2024 in Review

Artal Group sold out of Repare Therapeutics (RPTX) in Q2 2024, closing a stake of 700,000 shares — an estimated $3.3M sold.

Artal Group first reported a position in RPTX in Q2 2020 and held it in 16 quarters. The position peaked at $19.6M in Q4 2020. 61 funds tracked by Wall St. Rank hold RPTX as of Q2 2024.

Artal Group reported no remaining Repare Therapeutics position as of Q2 2024 after selling out during the quarter.
Artal Group sold 700,000 Repare Therapeutics shares in Q2 2024, an estimated $3.3M.
Artal Group first reported a position in Repare Therapeutics in Q2 2020 and held it in 16 quarters.
Artal Group's Repare Therapeutics position peaked at $19.6M in Q4 2020.
61 funds tracked by Wall St. Rank held Repare Therapeutics as of Q2 2024.

Based on Artal Group's 13F filing for Q2 2024, filed 14 Aug 2024.